Introduction
Telomere structure and function Telomeres are specialized DNA-protein structures that cap the ends of linear chromosomes. Mammalian telomeres are composed of the hexanucleotide of TTAGGG repeated from 5 ± 25 kilobase pairs in length oriented 5' to 3' toward the chromosome end (Allshire et al., 1989; Blackburn and Gall, 1978; deLange et al., 1990; Moyzis et al., 1988) . Several recent studies have suggested that the structure of the ends of telomeres may be more complex than originally thought. Grith and colleagues have found that telomeres do not end in a linear manner ( Figure 1a ) (Grith et al., 1999) . Instead the end of the telomere forms a loop structure with the 3' G-rich strand (referred to as the`T' loop) invading the duplex telomeric repeats, forming a displacement or D loop (Figure 1b) . Telomereassociated proteins may facilitate the formation and the maintenance of the both the T-and D-loops, suggesting a large DNA-protein structure at the end of each chromosome. In addition, most human telomeres appear to terminate in a single-stranded 3' GT-rich overhang, which is thought to play an important role in telomere structure and function (Colgin and Reddel, 1999; Makarow et al., 1997; Wright et al., 1997) . These fundamental new ®ndings of the structure of telomeres have enormous implications in the design of compounds that can target and disrupt the telomere structure by providing us with more targets for new drug development.
Telomeres are highly conserved in organisms ranging from unicellular eukaryocytes to mammals, indicating a strong preservation of their protective mechanisms for preventing chromosomal ends from undergoing degradation and ligation with other chromosomes. Without telomeric caps, human chromosomes would undergo end-to-end fusions with formation of dicentric and multicentric chromosomes (Counter et al., 1992; Harley, 1995; Harley et al., 1990; van Steensel et al., 1998) . These abnormal chromosomes would break during mitosis, resulting in severe damage to the genome and the activation DNA damage checkpoints and leading to cell senescence or the initiation of apoptosis cell death pathways (deLange and Jacks, 1999) .
In addition to protecting from end-to-end fusion of chromosomes, telomeres are also thought to protect against the loss of DNA at the end of each chromosome upon the completion of DNA replication. Dividing cells have been shown to undergo a progressive loss of 25-200 DNA base pairs following each cell division (Harley et al., 1990; Hastie et al., 1990; Mehle et al., 1994) . This loss of telomeric DNA is largely due to the`end replication problem' (Olovnikov, 1973; Watson, 1972 ) (see Figure 1a for classical (old) model of telomere ends). The`end replication problem' refers to the inability of the DNA replication machinery to copy the ®nal few base pairs of the lagging strand during DNA synthesis (Olovnikov, 1973; Watson, 1972) . Another possible cause for loss of telomeric sequence is by a 5' to 3' exonuclease activity which recesses the telomeric CArich strand (Makarow et al., 1997; Wellinger et al., 1996) . Since the telomere consists of a repetitive DNA sequence, its loss is thought to be less important to the cell than the loss of critical gene encoding sequences that may be near the end of a chromosome; therefore, telomeric sequences protect from the loss of more critical gene encoding sequences.
Telomere maintenance by telomerase
Normal human somatic cells have a limited replicative life span when grown as in vitro cell cultures. After approximately 50 cell divisions, these cells will enter cellular senescence (mortality stage 1 or M1), characterized by irreversible cell cycle arrest. It is now generally accepted that there is a causal relationship between telomere shortening and M1 senescence. This acceptance is based on many studies showing that the telomeres of normal diploid cells decrease as they are grown in culture, as well as studies showing the correlation of telomere length and age in human tissues (Harley, 1995; Harley et al., 1990) . These ®ndings support the hypothesis that telomere erosion is an important signal in the aging of a cell, leading to the induction of cellular senescence and cell death. The cumulative loss of telomeric DNA sequence acts as a biological clock, eventually limiting the replicative potential of cells when a critical telomere length is reached.
Since all replicating cells are subject to cell senescence caused by telomeric DNA loss, cells with long-lived replicative life spans need a mechanism to counteract or prevent this loss. One way cells have to restore telomeric DNA is the activation of the enzyme telomerase. Telomerase activity was initially described in the ciliate Tetrahymena, with subsequent studies leading to the molecular cloning of several of the components of the telomerase holoenzyme from many dierent organisms Blackburn, 1985, 1987; Henderson, 1995; Morin, 1989) . The telomerase enzyme is a reverse transcriptase ribonucleoprotein enzyme complex that is responsible for maintenance of the telomeric DNA at the end of chromosomes (Morin, 1989) . It is a very unique polymerase, as it uses its own RNA template to add repeats onto the G-rich strand (Harrington et al., 1997; Nakamura et al., 1997) . The complimentary C-rich strand is thought to be partially synthesized by other replication enzymes such as polymerase a (Colgin and Reddel, 1999) .
The basal human telomerase enzyme consists of at least two components, the catalytic subunit, hTERT, and the telomerase RNA, hTR (Collins et al., 1995; Harrington et al., 1997; Kilian et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997) . The various components of telomerase are encoded by distinct genes (Colgin and Reddel, 1999) . The catalytic subunit hTERT has seven protein domains in common with retroviral and retrotransposon reverse transcriptases. These conserved motifs are part of a protein fold that forms the active site of the enzyme and includes three aspartate residues that are critical for catalysis (Colgin and Reddel, 1999; Nugent and Lundblad, 1998) . There is an additional motif, T, which is speci®c to telomerase reverse transcriptases (Colgin and Reddel, 1999) .
Several variant hTERT mRNAs derived, presumably, from alternative splicing have also been described (Kilian et al., 1997) . It is possible that alternative splicing would play a role in regulating the activity of telomerase during development and dierentiation (Colgin and Reddel, 1999) . Of importance is that transfection of hTERT into hTR (telomerase mRNA) positive/telomerase negative cells results in telomerase activity, which suggests that hTERT may be ratelimiting for the assembly of a catalytically active telomerase (Beattie et al., 1998; Colgin and Reddel, 1999; Counter et al., 1998; Nakayama et al., 1998; Weinrich et al., 1997; Wen et al., 1998) .
Control of hTERT expression appears to be by transcriptional control but may also be through phosphorylation (Bodnar et al., 1996; Kilian et al., 1997; Ku et al., 1997; Li et al., 1997 Li et al., , 1998 Meyerson et al., 1997) . Of note is that c-myc can induce telomerase activity by increasing the transcription of hTERT (Wang et al., 1998) . There are c-myc binding sequences on the hTERT gene as well as binding sites for other transcription factors and hormone response elements, making the transcriptional control of hTERT expression an area of very active research (Cong et al., 1999) .
In addition to the above, it has recently been reported by Holt et al. (1999) and colleagues that the molecular chaperones p23 and Hsp90 bind to the catalytic subunit of telomerase. If one blocks the interaction of Hsp90 or p23 with the catalytic subunit of telomerase, the assembly of active telomerase is blocked in vitro. Inhibition of Hsp90 function in cells with geldanamycin (an Hsp90 inhibitor) blocks the assembly of active telomerase (Holt et al., 1999) . It has been suggested that Hsp90 and p23 act as à foldosome' that mediates the assembly of a biologically active protein complex (Holt et al., 1999) . Another protein, TEP-1, is also a component of the telomerase complex. The function of TEP-1 is still incompletely understood, but it may play a role in the transport and integration of telomerase into the Figure 1 The Classical (a) and New (b) view of the telomeric end structures (Grith et al., 1999) Oncogene Targeting telomere maintenance DJ Bearrs et al telomere. Additional proteins may be involved in the telomerase holoenzyme and may add functionality such as enzyme processivity.
Telomerase and cancer
Telomerase activity allows cells to maintain their telomeric DNA and avoid the M1 senescence checkpoint. This is a necessary process for normal cells that need the ability to proliferate inde®nitely such as germ line cells. Unfortunately, telomerase activity can also contribute to the inde®nite replicative capacity of cancer cells. Shortened telomeres have been documented in multiple tumor types taken directly from patients (see Table 1 ) and it is thought that there is a reduction in telomere length in almost all tumor cells compared to normal cells. Many studies have reported that telomerase is not active in most somatic tissue but is active in cancer cells and in germ cell tissues Kim et al., 1994; Raymond et al., 1996a; Shay and Bacchetti, 1997) . Table 2 summarizes our data and the data of others for the presence of telomerase activity in tumor cells taken directly from patients (Raymond et al., 1996b) . In general agreement with our data, a recent survey of the status of telomerase positive cells has suggested that close to 85% of human malignancies have telomerase activity, while less than 0.5% of normal cells are telomerase positive (Shay and Bacchetti, 1997) .
These data suggest that telomere shortening may function as a tumor suppressor mechanism and that activation of telomerase is an important step in overcoming this tumor suppression. This thought is strengthened by recent work that implicates telomerase activity as a necessary step in the tumorigenesis process. Hahn et al. (1999) in Dr Weinberg's laboratory have documented that expression of hTERT with SV40 large T antigen and H-ras results in direct conversion of normal cells to tumor cells. Expression of all three of these proteins is necessary to see this conversion, as expression of each protein alone is not sucient to cause the conversion (Hahn et al., 1999) . In addition, Bodnar et al. (1998) have documented that transfection of cells with hTERT results in elongation of telomeres and bypassing of crisis. This series of very important ®ndings helps validate telomerase as a very important anticancer drug target.
Telomerase as a drug target
The fact that telomerase activation appears to be a near-universal occurrence in cancer cells suggests that telomerase may be an Achilles heel of the tumor cell. If this is indeed correct, then inhibition of the telomerase enzyme would result in the erosion of telomeric DNA leading to the arrest of tumor cell growth or regression of the tumor due to the eects of sustained telomere erosion. Telomere shortening acts as a trigger for cells to either senesce or die, or upregulate telomerase and develop immortality or progress into tumor cells Counter et al., 1992; Harley, 1991; Levy et al., 1992; Lundblad and Szostak, 1989; Morin, 1989) . Since telomerase activity has been described in most tumor cells but not in many normal cells (see Table 3 ), there is the potential for relatively minor side eects (if any) of a telomerase-speci®c inhibitor. This gives us some hope for selectivity of telomerase inhibitors for tumor cells versus normal cells. Blackburn, 1994, 1996) . Several studies have reported the eects of azidothymidine triphosphate (AZT-TP), arabinofuranyl-guanosine triphosphate (Ara-GTP), dideoxyinosine triphosphate (ddITP), ddTTP, and ddGTP on telomerase activity Blackburn, 1994, 1996) . All of these nucleoside triphosphate analogs inhibit telomerase activity in vitro, but the analogs of AZT, 3'-deoxy-2',3'-didehydrothymidine (d4T), and Ara-G also caused a consistent and rapid telomere shortening in vegetatively growing Tetrahymena Blackburn, 1994, 1996) . More recently, the eects of AZT on telomere length of a murine metastatic melanoma cell line, K-1735 clone X-21, and a human breast cancer cell line, MCF-7, were determined (Multani et al., 1998) . Using¯uorescence in situ hybridization (FISH) analysis to measure telomere length, a signi®cant concentration-dependent decrease of telomeric signal intensity was seen in the AZT-treated cells, while no telomere shortening was observed in the untreated controls. These results suggest that nucleotide analogs may be able to disrupt the telomere maintenance of cancer cells by targeting the hTERT reverse transcriptase. Alternatives to the nucleotide analogs are the growing family of potent telomerase inhibitors that have been identi®ed through screening of chemical small molecule libraries using a telomerase assay. In one study, a group of isothiazolone-containing telomerase inhibitors were identi®ed to have submicromolar potency in a telomerase assay (Bare et al., 1998) . Since isothiazolones are known to react with the reduced thiols of cysteine and DTT, these compounds are proposed to interfere with telomerase activity by modifying a cysteine residue(s) in or near the reverse transcriptase active site of telomerase (Bare et al., 1998) . These results suggest that the use of a biochemical screening assay system that targets the reverse transcriptase activity of telomerase may be useful for identifying inhibitors of telomerase.
Antisense approaches A second approach for targeting hTERT protein is to use antisense oligonucleotides that are designed to hybridize with complementary sequences of hTERT mRNA and subsequently deplete hTERT protein levels inside cells. The recent clinical success of the ®rst antisense drug provides the impetus for the further development of these strategies for selective disruption of telomerase expression (Webb et al., 1997) . Since only the RNA component has been targeted in the area of telomerase-directed antisense strategies, in future studies it will be valuable to test the eect of an antisense drug designed to target hTERT.
Targeting the telomerase RNA The second essential component of the telomerase enzyme is the RNA template hTR. The RNA component of telomerase is divided into several unique domains that are critical for normal enzymatic function and assembly of the telomerase enzyme (Betts et al., 1995; Bhattacharyya and Blackburn, 1997; Blackburn, 1996, 1999; Gilley et al., 1995; Peer et al., 1993; Tzfati et al., 2000) . These domains include an alignment domain that facilitates substrate binding to the template domain for polymerization and non-template domains that are probably involved with the binding of the RNA to the telomerase protein components and further involved in modulating enzymatic activity. The RNA component is critical to the enzymatic function of telomerase. This has motivated a number of investigators to design telomerase inhibitors based on the sequence and structure of the telomerase RNA. Since the RNA component of telomerase is an ideal target for oligonucleotides that are able to recognize and hybridize to accessible complementary sequences of the RNA, several antisense strategies have been explored (Glukhov et al., 1998; Hamilton et al., 1999; Kushner et al., 2000; Pandit and Bhattacharyya, 1998; Pitts and Corey, 1998) .
A number of studies have been directed toward targeting the template domain of telomerase RNA with antisense oligonucleotides, and eective inhibition of telomerase activity has been achieved (Betts et al., 1995; Hamilton et al., 1997 Hamilton et al., , 1999 Peer et al., 1993) . Several dierent oligonucleotides with dierent chemical modi®cations have been tried, with a recent report suggesting that 2'-O-alkyl-RNA oligomers are more selective than peptide nucleic acids (PNAs) in binding to the complementary telomerase RNA sequences (Pitts and Corey, 1998) . Results from the same study have also shown that 2'-O-Me-RNA-based oligomers complexed with cationic lipids can eciently inhibit telomerase activity upon transfection of the human prostate tumor cell line DU145 (Pitts and Corey, 1998) .
Structural targeting
Other suggested approaches to target telomerase have focused on structure-based design of telomerase inhibitors based upon the threedimensional structures of functionally important domains of the enzyme. It is clear that as more information becomes available about the structural importance of dierent RNA components in telomerase function, targeting strategies using oligonucleotides or small molecules aimed at select RNA components of hTR may prove very promising in achieving selective inhibition of telomerase activity (Chen et al., 2000) .
Potential problems with targeting telomerase
As with most biological pathways, telomere maintenance may be much more complex than previously thought. In fact, telomere maintenance may not be simply a result of the activation of telomerase activity. It does appear that all immortalized cell lines have a telomere maintenance mechanism, but that mechanism can be either telomerase or an alternative mechanism called`alternative lengthening of telomeres' (ALT) (Colgin and Reddel, 1999; Niida et al., 2000) . There is a growing list of immortalized lines that have no detectable telomerase activity. Notwithstanding the absence of telomerase activity, these human cell lines maintain very long telomeres. This raises a crucial question for the future use of telomerase inhibitors as anticancer agents. If telomerase is inhibited in cancer cells that are maintaining their telomeres by telomerase, will these cells be able to activate the ALT pathway and therefore become resistant to the antitelomerase agents? This question has yet to be answered in vivo, but it raises the possibility that resistance mechanisms may be available and selected for in cancer cells treated with telomerase inhibitors. However, it is of note that most carcinoma-derived cell lines utilize upregulation of telomerase rather than an alternative mechanism of lengthening telomeres (Bryan et al., 1997; Colgin and Reddel, 1999) . In fact, the alternative mechanism of telomere maintenance appears to be present most often in human ®broblasts and other cells of mesenchymal origin and not in human carcinoma cells. Thus, telomerase would appear to be an excellent target in human carcinoma cells.
Another confounding issue facing the use of telomerase inhibitors as anticancer agents comes from the lessons learned from the telomerase knock-out mouse. These mice were generated through targeted disruption of the telomerase RNA gene (mTR) in mouse ES cells (Blasco et al., 1997) . The mTR knockout mice have no detectable telomerase activity but show no obvious ill eects through the ®rst ®ve successive generations of interbreeding. Interestingly, ®broblast cells derived from these mice display progressively shortening telomeres, suggesting that telomerase is necessary for maintenance of mouse telomeres, but is dispensable for the ®rst six generations of mice (Blasco et al., 1997). After six generations of interbreeding the mice develop some phenotypes, such as male sterility, that indicate that progressive telomere shortening causes disruptions in highly proliferative organs .
Cancer rates in the telomerase knock-out mice have been extensively examined. Interestingly, instead of having lower cancer rates, as one might expect, these telomerase null mice actually have slightly higher rates of tumor formation compared to controls (Rudolph et al., 1999) . How cancer formation is eected by loss of telomerase was also explored by breeding the telomerase RNA knock-out mice to the knock-out mice for the INK4A and p53 tumor suppressor genes Greenberg et al., 1999) . Once again, surprising and confounding results were generated by these interbreedings. Consistent with their roles as important tumor suppressors, both the INK4A and p53 knock-out mice are highly tumor prone. However, breeding these mice to the telomerase knock-outs resulted in opposite eects in each model, with the INK4A/mTR null mice displaying reduced tumor formation and the p53/mTR null mice showing increased tumor formation Greenberg et al., 1999) . These results suggest that loss of telomerase activity may have dierent eects on tumor development and progression based on the genetic background of a given cell. The fact that loss of telomerase activity can promote tumor formation in the presence of mutant p53 is cause for concern of the use of telomerase inhibitors in the clinic, especially in prolonged treatment schedules. However, how and if these mouse models translate to humans is still in question, especially in light of the fact that telomere maintenance in laboratory mouse cells is already known to dier from that of human cells, especially in the area of maintenance of telomere length (Blasco et al., 1997) .
With many questions still existing about the validity and feasibility of the use of telomerase inhibitors as anticancer agents, it is worth noting that no matter what mechanisms they use, cancer cells need to maintain telomeres to remain viable. Therefore, targeting telomere maintenance mechanisms as a whole (instead of just focusing on telomerase) may be a more eective drug development strategy. With the ongoing discovery of the structure and function of the telomere we now have many ways to target telomere maintenance mechanisms.
New strategies to target telomere maintenance mechanisms
Targeting T-loops One strategy for targeting the telomere maintenance mechanisms in the cell is to take advantage of the distinctive DNA structures that have been shown to form with telomeric DNA sequences. The unique structure and dynamics of T-loops found at the ends of telomeres provide a number of opportunities to selectively target telomere maintenance mechanisms. The T-loop consists of a duplex 6-base-pair repeat (dATTGGG) n with a G-rich singlestranded end that invades and closes into the duplex region to form an as yet undetermined secondary DNA structure (Grith et al., 1999) . In addition to the nucleic acid component, a number of proteins, including TRF1, TRF2, and probably telomerase, are associated with the T-loop structure (see Figure 1) . TRF1 is associated with the duplex telomeric repeat region, and its binding is determined by posttranscriptional modi®cation by the poly(ADP-ribose) polymerase tankyrase (Smith et al., 1998; Smith and de Lange, 1997 ). TRF2 appears to be associated with the junction site between the invading single-stranded telomeric sequence and duplex DNA, although it is not restricted to this site (see Figure 1) (Broccoli et al., 1997) . Because the single-stranded telomeric DNA sequence is sequestered in the junction with TRF2 and duplex DNA, it is unavailable for telomerase extension. Through as yet unde®ned events involving dissociation of TRF1 and TRF2 from the T-loop, the single-stranded telomeric end can become accessible to telomerase for reverse transcriptase activity, which leads to telomeric extension. Thus telomere extension by telomerase involves both structural and dynamic changes in the T-loop that go beyond the telomerase cycle of elongation and translocation.
The T-loop and postulated D-loop duplex ± singlestrand invasion junction are ideal targets for DNAinteractive agents. This is because the T-loop has a duplex telomeric repeat, providing multiple targets of the same sequence, and also speci®c secondary DNA structures associated with the invasion complex. This presents us with several unique opportunities to achieve unusual speci®city with DNA-interactive agents.
Telomeric duplex DNA has a 6-base-pair repeating sequence (5'-TTAGGG) n , and the binding of TRF1 dimers may result in the curvature necessary to form the T-loop. The c-Myb-like domain of TRF1 bound to duplex DNA structure shows major groove binding of the protein, leaving the minor groove accessible for drug modi®cation (Konig et al., 1998) . Thus drugs that interact in the minor groove of DNA and have a sequence speci®city that targets them toward telomeric sequences and distorts DNA structure may well disrupt the T-loop structure.
G-quadruplex targets At the very ends of telomeres are 150-to 200-base single-stranded DNA regions of the 3' (G-rich) strand. Because of the unique properties of G-rich sequences of DNA, they can form an unusual variety of secondary structures known as Gquadruplexes .
During the cell cycle, most likely at the end of the S phase, it seems reasonable that this single-stranded end must become accessible to telomerase or to other factors prior to re-sequestration within the T-loop junction at the so called D-loop site by TRF2 (see Figure 1) . We have proposed that within this window, the presence of small molecular weight`driver molecules' may facilitate the formation of secondary DNA structures such as G-quadruplexes (Figure 2 ), making these ends unavailable for either telomerase or sequestration into the D-loop structure .
A number of groups have been seeking to identify small organic molecules that bind to G-quadruplex structures with the aim to inhibit telomerase and thus disrupt telomeres Sharma et al., 1997) . Although the biological eects of G-quadruplexes might not be restricted to telomerase and telomeres, the primary targets of G-quadruplex-interactive agents at this stage are still telomerase and telomeres, primarily due to the lack of data concerning other cellular roles Sharma et al., 1997) .
Our research group, along with several others, has adopted a structure-based design and synthesis approach to the development of lead compounds that interact with G-quadruplexes, which has been very successful. To date, several groups of compounds have been identi®ed (Figure 3) , and their interaction with Gquadruplexes has been extensively studied.
Anthraquinone analogs were originally developed as DNA-interactive agents with cytotoxicity to a range of tumor cell lines (Agbandje et al., 1992) . The 2,6-diamido anthraquinones were shown to act as selective triplex-interactive compounds with reduced anity for duplex DNA (Haq et al., 1999) . Molecular modeling studies predicted that they might bind to G-quadruplex structures by a threading intercalation model (Tanious et al., 1992) . We ®rst showed by 1 H NMR that one of the analogs of the 2,6-diamido anthraquinone BSU-1051 (Figure 3) binds to and stabilizes G-quadruplex structures. We also demonstrated by using the direct telomerase assay that this compound inhibits telomerase through its interaction with the intramolecular Gquadruplex formed from the telomeric primer . A number of anthraquinone analogs have been recently identi®ed to interact with G-quadruplexes and inhibit telomerase, including some of the most potent small-molecule inhibitors of telomerase reported to date (Perry et al., 1999) .
Porphyrins have long been of particular interest in photodynamic cancer therapy, largely because of their ability to accumulate to a greater extent in tumor tissues rather than in normal tissues (Schuitmaker et al., 1996) . The planar arrangement of the aromatic rings in porphyrin analogs led us to propose that such compounds might be able to bind to G-quadruplexes through interactive stacking with the G-tetrads (Wheelhouse et al., 1998a,b) . By using spectroscopy, circular dichroism, and NMR, it has been shown that the porphyrin analog TMPyP4 (Figure 3 ) binds to and stabilizes both parallel and antiparallel G-quadruplex structures (Anantha et al., 1998; Wheelhouse et al., 1998a,b) . We have further shown that TMPyP4 can inhibit telomerase through G-quadruplex interaction with telomeric DNA, whereas its positional isomer TMPyP2 does not (Figure 3 ) (Han et al., 1999a; Wheelhouse, 1998a,b) . A photocleavage assay revealed that the dierence in G-quadruplex interaction between these two isomers results from their dierent binding sites in G-quadruplexes (Han et al., 1999a) . Two dierent G-quadruplex-binding models have been proposed for porphyrins. The ®rst model, based upon photocleavage data, predicts that porphyrin molecules externally stack to G-tetrads located at the ends of Gquadruplex, while the other proposes, on the basis of molecular modeling and stoichiometry measurements, that porphyrin molecules intercalate between two Gtetrads (Han et al., 1999a; Haq et al., 1999) . Although the spectroscopy data and molecular modeling studies support both models, photocleavage data provides the best experimental evidence for the external stacking model (Han et al., 1999a) .
Comparative studies using tumor cell lines found that TMPyP4 has a higher slowing eect on cell growth than the non-quadruplex-interactive compound TMPyP2, which is in accord with the telomerase inhibition data (Izbicka et al., 1999a,b) . TMPyP4 also induces anaphase chromosomal bridges in sea urchins, while TMPyP2 does not (Izbicka, 1999b) . This result indicates that G-quadruplex-interactive compounds might target the telomeres directly inside cells.
Perylene as a potential G-quadruplex-interactive agent was ®rst identi®ed by using the structure-based design program DOCK, developed by Irwin Kuntz at UCSF (Briem and Kuntz, 1996) . On the basis of molecular modeling data, Fedoro and co-workers designed and synthesized the N,N'-bis[2-(1-piperidino)-ethyl] -3, 4, 9, 10 -perylenetetracarboxylic diimide (PI-PER), which contains two positive charges at the ends (Figure 3 ). This compound turned out to be a very speci®c G-quadruplex-interactive agent that has little interaction with single-or double-stranded DNA. The NMR structure of a PIPER ± G-quadruplex complex (Figure 4) , the ®rst de®nitive structure of a ligand ± Gquadruplex complex, showed that the binding mode of PIPER to G-quadruplexes is similar to that proposed by us for the porphyrins, i.e. external stacking to Gtetrads (Fedoro et al., 1998) .
As with other G-quadruplex-interactive compounds, PIPER showed very good telomerase and DNA polymerase inhibitory activities (Fedoro et al., 1998) .
However, one of the most striking properties of this compound is its driver-like role in the assembly of Gquadruplex structures. PIPER not only converts the dimerization reaction of the dimeric G-quadruplex formation from second order to ®rst order, but it also increases the initial formation rate about 100-fold at a 10 mM concentration (Han et al., 1999b) . A similar eect has been observed in the facilitation of G-quadruplex formation by short G-rich oligonucleotides and by the b-subunit of the Oxytricha telomere binding protein, which is reportedly a G-quadruplex chaperone (Fang and Cech, 1993; Marco-Haviv et al., 1999) . This ®nding suggests that in addition to passive binding and stabilization, this type of compound may be able to play an inductive role in the formation of G-quadruplex structures within cells. In very recent studies we have also shown that PIPER, by binding to G-quadruplexes, inhibits their unwinding by Sgs1, a G-quadruplexspeci®c helicase from yeast .
It has been proposed, not unreasonably, that the invasion of the single-stranded telomeric end into the duplex telomeric region may involve a D-loop. It is also conceivable that an alternative secondary structure such as a G-quadruplex may be involved. Successful drug targeting of this structure will be dependent upon identi®cation of this DNA secondary structure; thus, as a prerequisite to drug design, this alternative secondary structure will need to be solved.
Posttranslational modification of telomere binding proteins
An attractive feature of the T-loop model is that it provides an explanation for how telomeres escape detection by DNA damage checkpoint proteins. However, it also seems logical that this structure must be disassembled and reassembled to allow telomere maintenance mechanisms to function. Figure 5 shows a scheme proposed by the Jacobsons for the involvement (Briem and Kuntz, 1996) . Thymine is shown in cyan, adenine in purple, guanine in yellow, and PIPER in green Targeting telomere maintenance DJ Bearrs et al of tankyrase and poly(ADP-ribose) glycohydrolase (PARG) in the disassembly and reassembly of a telomere loop structure (Jacobson and Jacobson, 1999) . The discovery of a component of telomeres containing poly(ADP-ribose) polymerase (PARP) activity has provided evidence for a direct involvement of ADPribose polymer cycles in telomere maintenance mechanisms (Smith et al., 1998) . This PARP, termed tankyrase, is a 142-kDa protein with a catalytic domain homologous to PARP-1, but otherwise it has a very dierent domain structure. Most notably, tankyrase contains 24 tandem repeats of the ankyrin motif, a 33 amino acid sequence motif that often links membrane proteins to the cell cytoskeleton. In contrast to the better-known PARP-1 and PARP-2, tankyrase does not appear to require DNA for activity, and it interacts with and catalyzes polymer modi®cation of the telomere-speci®c protein TRF1 in vitro. The domain structure for tankyrase and TRF1 and their interactions are shown in Figure 5 .
Thus, the telomere loop model suggests a role for tankyrase and PARG in disassembly and reassembly of the telomere loop structure as speculated in Figure 5 . The structure of ADP-ribose polymers results in a very high density of negative charges on the polymers, making them eective polyanions that can compete with DNA for DNA binding proteins. The tankyrasecatalyzed addition of negatively charged polymers to TRF1 is postulated to result in disassociation of TRF1 from telomere DNA and disassembly of the loop. In turn, PARG-catalyzed degradation of TRF1-associated polymers would result in the removal of the competing polyanion and thus facilitate reassembly of the loop. The model shown in Figure 5 is not meant to imply that ADP-ribose polymer cycles necessarily result in complete disassociation of the T-loop structure, only that they are capable of increasing access to telomere DNA. Telomere maintenance mechanisms where tankyrase and PARG may be involved include telomere replication, telomere repair, telomere length stabilization by telomerase, stable integration of telomerase into the telomere, and telomere recombination.
The unlimited proliferation potential of cancer cells is closely linked with their ability to maintain stable telomere structures. Thus, the disruption of telomere stability by targeting tankyrase suggests a new approach for cancer treatment. Most inhibitors developed to inhibit PARP-1 act at or near the nicotinamide region of the NAD-binding site of the enzyme, which is likely to have a similar structure in all PARPs. This is supported by the observations that 3-aminobenzamide inhibits the activity of each of the four known PARPs (Ame et al., 1999; de Murcia and Menissier de Murcia, 1994; Kickhoefer et al., 1999) . The discovery of multiple PARPs now dictates the design of inhibitors speci®c for dierent PARPs for both elucidation of function and therapeutic targeting of ADPR polymer cycles. Finally, PARG may be an important therapeutic target. The dynamic nature of polymer cycles indicates that PARPs and PARG function coordinately, thus inhibition (or activation) of PARG is expected to aect functions modulated by polymer cycles. The low homology of PARG to other known proteins and its structurally unique substrate suggest that highly selective PARG inhibitors could be developed. Furthermore, since each of the known PARPs undergoes automodi®cation, modulation of PARG might be an eective way to modulate these enzymes.
Conclusion
It is clear that telomere maintenance is important to all dividing cells, including cancer cells. The integrity of telomere maintenance mechanisms is essential for genomic stability and without proper telomere maintenance cells are subject to the activation of pathways leading to cell cycle arrest or cell death. This makes the telomere maintenance mechanisms prime targets for the development of anticancer agents.
Although telomerase activation is not the sole mechanism responsible for maintaining telomeric sequences, the enzyme appears to be crucial in the maintenance of telomeres for most cancer cells. In preclinical studies, telomerase inhibitors have shown promise as eective agents for a wide variety of malignancies, but their usefulness in the clinic have yet to be proven. In addition to telomerase, new discoveries have shed light on other proteins involved in the telomere maintenance mechanisms. Identifying and understating how these proteins are involved in telomere maintenance has added and will continue to add to the list of possible targets for therapeutic intervention. Other possible targets for the disruption of telomere maintenance are speci®c DNA structures, such as G-quadruplexes, that can form from telomeric sequences. Results from our group and others indicate that G-quadruplex-interactive compounds might target telomeres and disrupt telomere maintenance in cells, making these compounds attractive potential anticancer agents.
While telomerase and telomere maintenance mechanisms may not be the universal targets for cancer that they once were thought to be, we certainly believe that Figure 5 A speculative scheme for the involvement of tankyrase and poly(ADP-ribose) glycohydrolase (PARG) in the disassembly and reassembly of a telomere loop structure (Jacobson and Jacobson, 1999) . The black lines represent non-telomere DNA and the yellow and red lines represent C-rich and G-rich strands of telomere DNA, respectively. The telomere-speci®c proteins TRF1 and TRF2 form a loop structure to stabilize the G-rich overhang. Tankyrase-catalyzed addition of negatively charged ADP-ribose (ADPR) polymers to TRF1 results in dissociation of TRF1 from telomere DNA and disassembly of the loop. In turn, PARG-catalyzed degradation of TRF1-associated polymers allows reassembly of the loop. Nam refers to nicotinamide they will be important targets in future research aimed toward a successful strategy for curing cancer.
